Bold claim: the spotlight on GLP-1 receptor agonists is reshaping patient care, but it may also heighten risks for people with eating disorders. And this is the part most people miss: a surge of public discussion and widespread advertising about weight-loss drugs can unintentionally trigger or worsen harmful behaviours in those already vulnerable. Dr Kate Murphy, a psychiatrist and head of the public Queensland Eating Disorder Service, warns that patients with eating disorders are arriving to clinicians after having used or been prescribed GLP-1 receptor agonists.
She notes that weight loss narratives tend to attract broad attention, which can amplify concerns and pressure surrounding body image and dieting. Driving across the country, she observes countless adverts for medical weight management, reflecting how pervasive these messages have become. This environment may complicate clinical care for individuals with eating disorders, who may respond to weight-focused messaging in ways that undermine recovery or safety.
In this context, clinicians emphasize careful assessment before initiating GLP-1 receptor agonists, ongoing monitoring, and a thoughtful approach to weight management that prioritises physical and psychological wellbeing. The discussion around GLP-1 receptor agonists is ongoing, and viewpoints vary on their risks and benefits in vulnerable groups.
What do you think: should advertising and public discourse around weight loss drugs be more tightly regulated to protect at-risk populations, or does open discussion help patients make informed choices? Share your views in the comments.
